QIoT has signed a landmark agreement with Mayo Clinic in the USA to support the clinical development, validation, and commercial rollout of QIoTrak — the world’s first connected intercostal drain, developed as part of our ‘virtual ward from home’ solution for thoracic surgery and the wider surgical drain market.

The deal represents a significant milestone for our company and follows months of technical discussion and clinical review. It allows Mayo Clinic to lead the patient-facing pilot activity in the US, while QIoT retains responsibility for product refinement, certification, and commercial launch. We are initially deploying QIoTrak with Mayo Clinic and Royal Papworth Hospital in the UK. This dual-site validation will give us a robust evidence base to support launch in both markets.

What makes this deal significant is not just the clinical prestige of Mayo Clinic, but the structure of the collaboration. We are aligned on a shared vision of decentralising care and freeing up hospital resources, while improving patient outcomes through smarter monitoring. This is not a typical pilot — it is a co-development and commercial readiness pathway with one of the most respected healthcare brands in the world.

Impact on Patients and Clinicians

QIoTrak enables post-surgical thoracic patients to leave hospital sooner and recover at home without losing clinical oversight. The solution provides clinicians with real-time insight into air leaks, fluid output, and other critical recovery data, helping prevent avoidable complications. For patients, it reduces time in hospital and allows them to heal in a familiar environment with greater peace of mind.

Clinicians benefit from earlier detection of issues, more efficient use of time and beds, and data-driven assurance that patients are recovering safely. In both UK and US settings, this model of post-surgical remote recovery is gaining traction — and QIoTrak is at the forefront of making it a reality.

Being chosen by Mayo Clinic to take this solution forward is a clear validation of our work to date. It also opens the door to wider adoption in the US and globally, helping us scale faster, supported by one of the most trusted names in healthcare.

We welcome enquiries from healthcare providers or clinical teams interested in participating in future deployments — as well as from investors aligned with our mission to transform post-surgical care through intelligent, connected recovery.